All In Biotech

Drug Trial Radar · NCT04991506

A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors

An Open-label, Multicenter, Dose-escalation and Cohort Expansion Phase 1 Clinical Study of ES102 in Combination With JS001 in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Oct 15, 2021

Primary completion

May 17, 2024

Study completion May 17, 2024

Sponsor

Lead sponsor
Elpiscience Biopharma, Ltd.Industry
Sponsor type
Industry
Collaborators
Shanghai Junshi Bioscience Co., Ltd.
First posted
Aug 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerance, Dose-Limiting Toxicity (DLT), Maximum tolerated dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of ES102 (OX40 agonist) in combination with JS001 (anti-PD-1 checkpoint inhibitor) in patients with advanced solid tumors.

Conditions

  • Solid Tumor
  • Neoplasms
  • Malignant Tumor

Interventions

  • ES102Drug

    The active ingredient of ES102 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4)

  • JS001Drug

    JS001 is administered via intravenous injection once every 21 days, every 21 days as a treatment cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MTDTime frame: 2-4 years
  2. Frequency and severity of adverse events of ES102 in combination with JS001Time frame: 2-4 years
  3. RP2DTime frame: 2-4 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jilin Cancer Hospital

    Changchun, Jilin, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.